Last reviewed · How we verify
NCT02528071: SLA
Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis
trial testing Diaphragmatic endurance test in ALS (Amyotrophic Lateral Sclerosis) in 136 participants. Terminated before completion.
28 October 2020
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de Saint Etienne |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 136 |
| Start date | 29 September 2014 |
| Primary completion | 28 October 2020 |
| Estimated completion | 28 October 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- Diaphragmatic endurance test
Conditions studied
- ALS (Amyotrophic Lateral Sclerosis) — all drugs for ALS (Amyotrophic Lateral Sclerosis) →
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Who can join
Adults 18 to 80, any sex, with ALS (Amyotrophic Lateral Sclerosis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease which involves respiratory muscles and can lead at short term to respiratory failure. The occurrence of respiratory failure is associated with morbidity and an increased mortality. To date, respiratory muscle weakness is predicted from the reduction of vital capacity, maximal inspiratory force, nocturnal symptoms and hypercapnia. Even taken together, the predictive value of these indices is low. The investigators hypothesize that an endurance test of diaphragmatic work would be more sensitive to respiratory muscle involvement than maximal respiratory force. Consequently, the investigators assessed diaphragmatic performance through an isocapnic hyperventilation test (IHT) in patients at the onset of ALS and, then regularly up to the occurrence of respiratory failure. The investigators make the hypothesis that IHT will be altered earlier than maximal inspiratory force
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02528071
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ALS (Amyotrophic Lateral Sclerosis)
Currently open trials in the same condition.
- NCT07067229 — Non-invasive Brain Stimulation and Exercise Intervention for Patients With Motor Neuron Disease · NA · recruiting
- NCT07006571 — At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis · NA · recruiting
- NCT07175935 — Amyotrophic Lateral Sclerosis Registry in Thailand · recruiting
- NCT07235111 — Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases · recruiting
- NCT06810219 — Augmented Reality BCI Longitudinal Study for Persons With Late Stage ALS · NA · recruiting
Other Centre Hospitalier Universitaire de Saint Etienne trials
Trials by the same sponsor.
- NCT07326579 — Effects of a Sleep Education Program on the Health Status of Healthcare Workers Working 12-hour Alternating Day-night Sh · NA · not yet recruiting
- NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
- NCT07483710 — Association Between Muscle L3 CT Scan Muscle Derived Parameters of Muscle Function Upon Intensive Care Unit Admission an · NA · not yet recruiting
- NCT06845176 — Combining Motor Imagery and Tendon Vibration on the Effectiveness of Motor Imagery · NA · recruiting
- NCT07344298 — Less is Better? Effectiveness of a Short Local Vibration Protocol on Neuromuscular Function · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02528071 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Saint Etienne
- Last refreshed: 5 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02528071.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing